PathAI Stock
PathAI is developing cutting-edge technology that promises to better diagnose—and treat—some of today's most challenging diseases.
Sign up today and learn more about PathAI Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About PathAI Stock
PathAI’s services solve the most challenging pathology problems faced by the research and pharmaceutical industry. The PathAI platform provides end-to-end automation for reliable, scalable, and cost-effective long-term solutions. PathAI is developing technology that assists pathologists in making rapid and accurate diagnoses for every patient, every time. The company was founded in 2016 and based in Boston, Massachusetts.
Investors
General Catalyst Partners
Snap, Jet, Stripe, Relativity Space, Devoted Health, Lacework, Oscar Health, Circle, Hopin, Vroom
General Atlantic
AppDynamics, Toutiao, Chime, Wish, Avant, Articulate, Bolt Financial, Automation Anywhere, Coalition, Blend
Funding History
| December 2016 | $4.2M |
|---|---|
| November 2017 | $11.0M |
| April 2019 | $60.0M |
| November 2019 | $15.0M |
Management
Co-founder & CEO
Andrew Beck
Co-founder & CTO
Aditya Khosla
Senior Software Engineer
Nicholas Vecellio
Independent Product Management Consultant
Gopal Shenoy
Press
pharmaphorum - Feb, 22 2024
Roche, PathAI team up on AI companion diagnosticsmarketscreener - Feb, 20 2024
Roche: new AI collaboration with PathAIprnewswire - Feb, 13 2024
Roche enters into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnosticsthehealthcaretechnologyreport - Dec, 27 2023
The Top 25 Women Leaders in Biotechnology of 2023beckershospitalreview - Dec, 27 2023
Health system-backed PathAI cuts 87 jobsEquityZen Recognized As:
